CD8A and neoplasm: Although we have not shown that similar profiles can identify tumor antigen-responsive CD8+ T cells, it is likely that the identification of TCRs using a similar approach may facilitate the development of chimeric antigen receptor T cell-based therapies that are patient-specific.